ArticleFrontiers in pharmacology2023
Myricetin attenuates hypoxic-ischemic brain damage in neonatal rats
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Sirtuins in intervertebral disc degeneration: current understanding.Molecular medicine (Cambridge, Mass.) · 2024Pooled it
- Encephalopathy: Cause, Pathogenesis, and Treatment.MedComm · 2026Review
- Exploring myricetin: A comprehensive review of its pharmacological potential, formulation strategies, and clinical outlook.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Bioactive Components ofAntioxidants (Basel, Switzerland) · 2026Review
- Novel purine derivatives mitigate hypoxia ischemia related brain injury through agrin, zyxin and synaptotagmin proteins.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Oxidative stress in pediatric diseases associated with the origin of life and growth and development.Frontiers in cell and developmental biology · 2025Review
- Exploring the Neuroprotective Potentials of Flavonoid Metabolites inJournal of experimental pharmacology · 2025Review
- The Neuroprotective Mechanisms of PPAR-γ: Inhibition of Microglia-Mediated Neuroinflammation and Oxidative Stress in a Neonatal Mouse Model of Hypoxic-Ischemic White Matter Injury.CNS neuroscience & therapeutics · 2024Article
- Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.Scientific reports · 2024Article
- Effects ofAntioxidants (Basel, Switzerland) · 2024Article
- LncRNA-mir3471-limd1 regulatory network plays critical roles in HIBD.Experimental brain research · 2024Article
- Recent studies on myricetin and its biological and pharmacological activities.EXCLI journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.